Cantor Fitzgerald Analysts Give Mylan N.V. (MYL) a $34.00 Price Target
“News outlets today reported State attorney generals are seeking to sue Mylan’s president and executive director, Rajiv Malik, as part of a civil investigation, according to Connecticut Attorney General George Jepsen.”,” Cantor Fitzgerald’s analyst wrote.
Several other analysts have also recently commented on the stock. Zacks Investment Research raised shares of Mylan N.V. from a sell rating to a hold rating in a research note on Tuesday, August 1st. Royal Bank Of Canada set a $41.00 target price on shares of Mylan N.V. and gave the stock a hold rating in a research note on Sunday, July 16th. Citigroup Inc raised shares of Mylan N.V. from a neutral rating to a buy rating and lifted their target price for the stock from $36.00 to $42.00 in a research note on Wednesday, August 16th. BTIG Research lifted their target price on shares of Mylan N.V. from $42.00 to $45.00 and gave the stock a buy rating in a research note on Wednesday, October 4th. Finally, Cowen and Company reaffirmed a hold rating and issued a $43.00 target price on shares of Mylan N.V. in a research note on Thursday, August 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. Mylan N.V. currently has an average rating of Buy and a consensus price target of $41.21.
Mylan N.V. (NASDAQ MYL) traded down $1.13 during mid-day trading on Tuesday, reaching $35.72. 5,459,113 shares of the company’s stock traded hands, compared to its average volume of 5,257,907. The stock has a market capitalization of $18.95 billion, a PE ratio of 7.10, a PEG ratio of 1.91 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 0.84 and a debt-to-equity ratio of 1.20.
Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm’s revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.16 earnings per share. analysts predict that Mylan N.V. will post 4.63 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Cantor Fitzgerald Analysts Give Mylan N.V. (MYL) a $34.00 Price Target” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-mylan-n-v-myl-a-34-00-price-target/1676850.html.
Several large investors have recently bought and sold shares of MYL. Meeder Asset Management Inc. lifted its holdings in shares of Mylan N.V. by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after acquiring an additional 1,475 shares in the last quarter. BT Investment Management Ltd acquired a new position in shares of Mylan N.V. during the 3rd quarter valued at $142,000. Global X Management Co. LLC lifted its holdings in shares of Mylan N.V. by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after acquiring an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP purchased a new stake in Mylan N.V. during the 2nd quarter worth $201,000. Finally, Eagle Global Advisors LLC purchased a new stake in Mylan N.V. during the 2nd quarter worth $205,000. Institutional investors and hedge funds own 72.03% of the company’s stock.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.